Vernal Keratoconjunctivitis Market
- 2026 年市場規模
- USD 414.0 Mn
- 2033 年預估規模
- USD 530.3 Mn
- 年複合成長率 CAGR
- 3.6%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Vernal Keratoconjunctivitis Market, By Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, Others), By Treatment (Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroids, Cyclosporine, Tacrolimus, Others), By Dosage Form (Gel, Ointment, Tablet, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
The inner surface of the eyelid is lined with conjunctiva, a translucent tissue layer. When infected, this tissue tends to cover the white area of the eye and turn red or pink. As a result, the eye ailment conjunctivitis is often known as pink eye. The infection of the eye known as conjunctivitis is a common symptom of this ophthalmic condition. Infectious causes includes bacterial and viral infections, while non-infectious causes include allergy and immune-mediated illness inflammation. It is categorised into acute conjunctivitis, super acute conjunctivitis, and chronic conjunctivitis.
Vernal keratoconjunctivitis (VKC) is a chronic, multifactorial Th2-cell-mediated inflammatory disease of the ocular surface. It is distinguished by a large papilla on the upper tarsal conjunctiva and a corneoscleral junction. Hyperemia and mucus discharge are typical symptoms of VKC. There is no set standard treatment strategy for VKC. Mast cell stabilisers, antihistamines, nonsteroidal anti-inflammatory medications (NSAIDs), topical corticosteroids, and cyclosporine are available as treatments. Individuals receiving treatment should be continuously observed for the development of any ocular problems.
Market Dynamics
Increasing R&D activities in vernal keratoconjunctivitis for a better understanding of the disease is expected to drive the growth of global vernal keratoconjunctivitis market during the forecast period. In addition, increasing prevalence of vernal keratoconjuctivitis and supportive therapies have built the interest in several pharmaceutical companies in developing a cure for the disease. A greater knowledge of the disease's biology and manifestation of the disease has boosted efforts to develop improved treatment alternatives in the form of pipeline treatments, which is projected to propel the global vernal keratoconjunctivitis market share during the forecast period.
Key features of the study
• This report provides an in-depth analysis of the global vernal keratoconjunctivitis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global vernal keratoconjunctivitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
• Key companies covered as a part of this study include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global vernal keratoconjunctivitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global vernal keratoconjunctivitis market
Market Segmentation
• By Drug Type (Revenue, USD Mn, 2021-2033)
o Bertilimumab
o Verkazia
o Lodoxamide
o Tacrolimus
o Antolimab
o Nomacopan
o Others
• By Treatment (Revenue, USD Mn, 2021-2033)
o Mast Cell Stabilizers
o Antihistamines
o Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
o Topical Corticosteroids
o Cyclosporine
o Tacrolimus
o Others
• By Dosage Form (Revenue, USD Mn, 2021-2033)
o Gel
o Ointment
o Tablet
o Others
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• By Region (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Santen
o Novartis Pharmaceuticals
o Senju Pharmaceutical
o Allakos
o iCo Therapeutics
o Akari Therapeutics
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Treatment
Market Snapshot, By Dosage Form
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Vernal Keratoconjunctivitis Market, By Drug Type, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Bertilimumab
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Verkazia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Lodoxamide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Tacrolimus
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Antolimab
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Nomacopan
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
5. Global Vernal Keratoconjunctivitis Market, By Treatment, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Mast Cell Stabilizers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Antihistamines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Topical Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Cyclosporine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Tacrolimus
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
6. Global Vernal Keratoconjunctivitis Market, By Dosage Form, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Gel
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Ointment
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Tablet
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
7. Global Vernal Keratoconjunctivitis Market, By Distribution Channel, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
8. Global Vernal Keratoconjunctivitis Market, By Region, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o North Africa
o Central Africa
o South Africa
9. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Santen
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Senju Pharmaceutical
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Allakos
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
iCo Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Akari Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
10. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們